← ANALYST RATINGS · TIPRANKS
Twist Bioscience (TWST): analyst forecast and price target
Analyst consensus
Moderate Buy8 Buy2 Hold1 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $158, the highest $215, the lowest $45.00. The average is +19.1% from the last price of $133.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $181 → $144−20.4% | Hold | +8.5% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $177 → $141−20.3% | Hold | +6.2% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $174 → $139−20.1% | Hold | +4.7% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $175 → $139−20.6% | Hold | +4.7% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $186 → $148−20.4% | Buy | +11.5% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $174 → $139−20.1% | Hold | +4.7% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $115 → $190+65.2% | Buy | +43.1% | Assigned | 13.10.26on TipRanks 09:00 | −0.3%next day −1.0% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $120 → $205+70.8% | Buy | +54.4% | Reiterated | 12.10.26on TipRanks 05:10 | −4.9%next day −0.3% | ↗ |
| Matthew Stanton, CFA★★★★★★★★★★#10524 · hits 43% · avg −10.9% | Jefferies | $150 | Hold | +13.0% | Initiated | 07.10.26on TipRanks Oct 8 05:30 | −6.5%next day −1.9% · 5 days −3.8% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $112 → $215+92.0% | Buy | +62.0% | Reiterated | 07.10.26on TipRanks 03:55 | −6.5%next day −1.9% · 5 days −3.8% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $107 → $212+98.1% | Buy | +59.7% | Reiterated | 01.10.26on TipRanks 08:35 | −2.9%next day −0.4% · 5 days −20.4% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $160 → $190+18.8% | Buy | +43.1% | Reiterated | 29.09.26on TipRanks 08:50 | +3.8%next day +4.0% · 5 days −12.2% | ↗ |
| Hamed Khorsand★★★★★★★★★★#435 · hits 56% · avg +16.8% | BWS Financial | $45.00 | Sell | −66.1% | Reiterated | 18.09.26on TipRanks 10:35 | +7.2%next day −2.2% · 5 days +8.2% | ↗ |
| Unknown Analyst | UBS | $144 | Hold | +8.5% | Initiated | 08.09.26on TipRanks Sep 10 08:05 | +3.2%next day −1.5% · 5 days +9.0% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $115 | Buy | −13.4% | Assigned | 05.08.26on TipRanks 07:30 | +15.9%next day −5.0% · 5 days +8.5% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $113 → $115+1.8% | Buy | −13.4% | Reiterated | 04.08.26on TipRanks 06:45 | −3.4%next day +15.9% · 5 days +23.9% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 03.08.26on TipRanks 15:45 | +9.0%next day −3.4% · 5 days +21.5% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $66.00 → $102+54.5% | Hold | −23.2% | Downgrade | 06.07.26on TipRanks 08:10 | −0.2%next day −8.4% · 5 days −9.3% | ↗ |
| Steven Etoch★★★★★★★★★★#2413 · hits 86% · avg +59.3% | Stephens | $41.00 | Buy | −69.1% | Initiated | 03.11.25on TipRanks 17:30 | −3.6%next day +4.5% · 5 days +3.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Twist Bioscience
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $127 at a price of $193 (−34.3%); now: $158 at $133 (+19.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 14 | 17 | 17 | 13 | 10 | 12 |
| Hold | 0 | 0 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 2 | 2 |
Earnings and sales forecast
Next report: 13.11.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.39 (from $-0.45 to $-0.34). Last quarter: $-0.56.
Sales
Next quarter’s sales estimate — $124M (from $123M to $124M). Last quarter: $118M.
Best top-analyst consensus in the sector · Healthcare
About Twist Bioscience
- CEO: Emily Marine Leproust
- Employees: 979
- 681 Gateway Boulevard, South San Francisco, CA, 94080, US
- www.twistbioscience.com
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 69 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗